Abstract

CRISPR-based therapies have revolutionized the field of gene editing, offering unprecedented potential for treating genetic disorders and various diseases. However, the successful application of these therapies is heavily dependent on the effectiveness of delivery mechanisms and the overall biopharmaceutics of CRISPR constructs. This article provides a comprehensive review of the current strategies for delivering CRISPR-based therapeutics, including viral vectors, nanoparticles, and other innovative methods. We analyze the efficacy of these delivery systems in preclinical and clinical settings, discuss their advantages and limitations, and explore recent advancements aimed at improving the precision and efficiency of CRISPR gene editing. The review also addresses the pharmacokinetics and pharmacodynamics of CRISPR therapies, offering insights into how these factors influence therapeutic outcomes. By evaluating these aspects, we aim to provide a holistic understanding of the biopharmaceutics of CRISPR-based therapies and highlight future directions for enhancing their clinical application.